x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012841
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Sin1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MAPKAP1 |
| UniProt No. | Q9BPZ7 |
| Gene ID | 79109 |
| Gene Description | Cell growth is a fundamental biological process whereby cells accumulate mass and increase in size. The mammalian TOR pathway regulates growth by coordinating energy and nutrient signals with growth factor-derived signals. mTOR is a large protein kinase that is a component of two different complexes. The mTOR complex 1, a target of rapamycin, contains mTOR, GβL, and raptor. mTORC2, insensitive to rapamycin, includes mTOR, GβL, Sin1, and rictor. The mTORC2 complex phosphorylates Ser473 of Akt/PKB in vitro. This phosphorylation is essential for full Akt/PKB activation. Furthermore, an siRNA knockdown of rictor inhibits Ser473 phosphorylation in 3T3-L1 adipocytes. mTORC2 has also been shown to phosphorylate the rapamycin-resistant mutants of S6K1, another effector of mTOR. In addition, phosphorylation of Sin1 at Thr86 by Akt/PKB was shown to regulate the activity of mTORC2 in adipocytes upon stimulation by growth factors. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
